Contact our breast care nurses 0808 800 6000

Breast Cancer Now media statements

103 results
Media Statement
We respond to the Royal College of Radiologists’ clinical radiology and clinical oncology census reports for 2021

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the Royal College of Radiologists’ clinical radiology and clinical oncology census reports for 2021.

10 Jun 2022

Media Statement
We respond to new findings from the Lumina trial which suggest some patients could avoid radiotherapy

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, expressed excitement about the new findings from the Lumina trial, which suggest some patients could avoid radiotherapy.

07 Jun 2022

Media Statement
We comment on new research which shows the drug trastuzumab deruxtecan may benefit even more breast cancer patients

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said it's exciting that the drug trastuzumab deruxtecan may benefit even more breast cancer patients.

05 Jun 2022

Media Statement
We welcome NICE approval of pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) for routine use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said today's approval of pembrolizumab (Keytruda) in combination with chemo for use on the NHS was absolutely fantastic news.

25 May 2022

Media Statement
We comment on saliva samples used to determine breast cancer risk in women of screening age

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, commented on new research into whether saliva samples can help determine breast cancer risk in women of screening age.

23 May 2022

Media Statement
We support latest Emmerdale storyline on Faith Dingle's Secondary Breast Cancer diagnosis

Catherine Priestley, Clinical Nurse Specialist at Breast Cancer Now, responded to the latest Emmerdale storyline about Faith Dingle's Secondary Breast Cancer diagnosis.

17 May 2022

Media Statement
We respond to new research into how salt in tumours could help diagnose and treat breast cancer

Dr Simon Vincent, Breast Cancer Now’s Director of Research, Support and Influencing, commented on new research investigating how salt in tumours could help diagnose and treat breast cancer.

25 Apr 2022

Media Statement
We respond to NICE provisional decision not to recommend alpelisib with fulvestrant for routine use on the NHS

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said it's disappointing that the National Institute for Health and Care Excellence has provisionally been unable to approve alpelisib with fulvestrant for routine use on the NHS.

01 Apr 2022

Media Statement
We respond to research about artificial sweeteners and breast cancer risk

Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, commented on a new study about artificial sweeteners and breast cancer risk.

24 Mar 2022

Media Statement
We respond to new data from major trial OlympiA that shows one year of adjuvant olaparib improved survival in patients with primary HER-2 negative breast cancer with an altered BRCA 1 or 2 gene

Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said it's exciting that new data from major trial OlympiA showed adjuvant olaparib improved survival in patients.

16 Mar 2022

Media Statement
We respond to NHS England breast cancer waiting times: January 2022

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to NHS England breast cancer waiting times on January 2022.

10 Mar 2022

Media Statement
We respond to NHS England's proposed new standards

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, expressed concerns about NHS England's proposed new standards for rapid cancer diagnosis.

09 Mar 2022